Likewise, recombinant leptin and metreleptin (leptin analog), administered for lipodystrophy and congenital leptin deficiency, have been reported to reverse hepatic lipid accumulation and reduce the consequences of NASH [53]. This evidence concerns the gene LEP and metabolic dysfunction-associated steatohepatitis.